News | Prostate Cancer | July 15, 2016

Photoacoustic Imaging Is Promising Option for Noninvasive Monitoring of Prostate Cancer

Imaging technology may lead to better monitoring of prostate tumors and treatment decision-making

photoacoustic imaging

Images of prostate cells captured through photoacoustic imaging. Top: cancer cells that express the targeted cancer marker, PSMA; bottom: cells that lack PSMA. A research team led by Kent Nastiuk of Roswell Park Cancer Institute has published new evidence that this approach can be a useful tool in monitoring and selecting treatments for many cancers.

While active surveillance is often recommended for patients with nonaggressive prostate cancer to reduce unnecessary treatment, the challenge for clinicians is to monitor and distinguish early-stage tumors from advanced cancers. A team of scientists led by researchers from Roswell Park Cancer Institute have demonstrated that photoacoustic imaging (PAI) may be an effective tool for more accurately viewing and monitoring prostate cancer. The new research has been published in the June 2016 issue of the Journal of Biomedical Optics.

Photoacoustic imaging is an emerging noninvasive imaging modality that has not yet been used in clinical settings. Using photoacoustic imaging, this team of scientists focused a laser light on prostate cells and then “listened” using ultrasound technology to see how a dye attached to a specific prostate cancer marker, PSMA, reacted to the light waves. They chose to study this technology’s use in imaging prostate cancer, as the prostate can be imaged in situ. Photoacoustic imaging of these prostate cells, the researchers found, enabled good discrimination between cells with and without the cancer marker.

“This proof-of-concept study demonstrates that this technology may allow for real-time monitoring of prostate cancer in patients during the course of active surveillance. For patients with more aggressive disease, the technology could offer more precise targeting of biopsies to confirm the need for definitive therapy,” said senior author of the study Kent Nastiuk, Ph.D., assistant professor of cancer genetics and genitourinary cancers at Roswell Park. “This technology offers the potential to confirm the initial prostate cancer diagnosis, guide biopsies and monitor tumor volume — which is currently not measureable — for improved case management and treatment decision-making.”

Nastiuk’s co-authors include scientists from Roswell Park Cancer Institute, the University of Rochester and the Rochester Institute of Technology.

The study, “Photoacoustic Imaging with an Acoustic Lens Detects Prostate Cancer Cells Labeled with PSMA-targeting Near Infra-red Dye-conjugates,” is available at biomedicaloptics.spiedigitallibrary.org.

This work was supported by the National Cancer Institute (project nos. R01CA151753, R15CA192148 and P30CA16056), National Institute of Biomedical Imaging and Bioengineering (project no. R15EB019726), National Institute of Arthritis and Musculoskeletal and Skin Diseases (project no. P30AR061307), the U.S. Department of Defense (award no. W81XWH-14-1-0242) and the Sonya A. Sinicki Foundation for Cancer Research (award 615SF).

 

Related Content

Civco Medical Solutions Introduces Envision Viral Barrier at RSNA 2018
News | Ultrasound Imaging | November 20, 2018
Civco Medical Solutions will present Envision, the next generation of ultrasound probe covers and scan pads, at the...
Philips Launches IntelliSpace Discovery Research Platform at RSNA
Technology | Artificial Intelligence | November 20, 2018
Ahead of the 2018 Radiological Society of North America Annual Meeting (RSNA), Nov. 25-30 in Chicago, Royal Philips...
Bay Labs and Northwestern Medicine Enroll First Patient in AI Echocardiography Study
News | Cardiovascular Ultrasound | November 19, 2018
Medical artificial intelligence (AI) company Bay Labs and Northwestern Medicine announced that the first patient has...
QView Medical Showcases QVCAD for ABUS Exams at RSNA 2018
News | Ultrasound Women's Health | November 19, 2018
QView Medical will showcase QVCAD, the first U.S. Food and Drug Administration (FDA)-approved artificial intelligence (...
Immune Inflammatory Levels Linked to Disease-Free Survival in Prostate Cancer
News | Prostate Cancer | November 19, 2018
Data from a validation study of a high-risk prostate cancer trial suggests that higher levels of pretreatment...
Life Image and Mendel.ai Bringing Artificial Intelligence to Clinical Trial Development
News | Artificial Intelligence | November 15, 2018
Life Image and Mendel.ai announced a new strategic partnership that will facilitate the adoption and enhancement of...
Artificial Intelligence Predicts Alzheimer's Years Before Diagnosis
News | Neuro Imaging | November 14, 2018
Artificial intelligence (AI) technology improves the ability of brain imaging to predict Alzheimer’s disease, according...
SuperSonic Imagine Introduces Aixplorer Mach 30 Ultrasound at The Liver Meeting
Technology | Ultrasound Imaging | November 14, 2018
SuperSonic Imagine recently exhibited at The Liver Meeting, held Nov. 9-13 in San Francisco, where the company...
New Robotic Arm System Optimizes Testing of Ultrasound Probes

Image courtesy of Esaote

News | Ultrasound Imaging | November 09, 2018
Medical imaging company Esaote and The BioRobotics Institute of Scuola Superiore Sant’Anna in Pisa, Italy, have...